Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4164-4169

  Boddy, Alan V ^a   Sludden, Julieann ^a   Griffin, Melanie J ^a   Garner, Colin ^c   Kendrick, John ^c   Mistry, Pritesh ^c   Dutreix, Catherine ^d   Newell, David R ^a   O'Brien, Stephen G ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Xceleron Ltd   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CGP 74588; IMATINIB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HUMAN; LEUKOCYTE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MASS SPECTROMETRY; MIDDLE AGED; PARTICLE ACCELERATORS; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES;

EID: 34547113063     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2179     Document Type: Article

References (31)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose Ara-C for newly-diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Hofmann WK, Komor M, Hoelzer D, Ottmann OG. Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 2004;45:655-60.
3. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-505.
4. Shah N, Nicoll J, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117.
5. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64:672-7.
6. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 acid glycoprotein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9:625-32.
7. Larghero J, Leguay T, Mourah S, et al. Relationship between elevated levels of the α1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec (R)) in vitro and in vivo. Biochem Pharmacol 2003;66:1907-13.
8. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577-82.
9. Burger H, Nooter K. Pharmacokinetic resistance to imatinib mesylate - role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 2004;3:1502-5.
10. Serkova N, Boros LG. Detection of resistance to imatinib by metabolic profiling - clinical and drug development implications. Am J Pharmacogenomics 2005;5:293-302.
11. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 2005;60:35-44.
12. Ramalingam S, Lagattuta TF, Egorin MJ, Hayes MJ, Ramanathan RK. Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. Pharmacotherapy 2004;24:1232-5.
13. le Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004;53:313-23.
14. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;33:1503-12.
15. Nikolova Z, Peng B, Hubert M, et al. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 2004;53:433-8.
16. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec (R)) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158-62.
17. Combes RD, Berridge T, Connelly J, et al. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci 2003;19:1-11.
18. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 2001;31:619-32.
19. Garner RC. Accelerator mass spectrometry in pharmaceutical research and development - a new ultrasensitive analytical method of isotope measurement. Curr Drug Metab 2000;1:205-13.
20. Lappin G, Garner RC. Current perspectives of C-14-isotope measurement in biomedical accelerator mass spectrometry. Anal Bioanal Chem 2004;378:356-64.
21. Vogel JS. Rapid Production of Graphite without Contamination for Biomedical AMS. Radiocarbon 1992;34:344-50.
22. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High-throughput quantification of the antileukemia drug ST1571 (Gleevec (TM)) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002;768:325-40.
23. Stumpe M, Miller C, Morton NS, Bell G, Watson DG. High performance liquid chromatography determination of α-1-acid glycoprotein in small volumes of plasma from neonates. J Chromatogr B 2006;831:81-4.
24. Piazza RG, Magistroni V, Andreoni F, et al. Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph plus chronic myeloid leukemia patients. Leukemia 2005;19:1985-7.
25. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-7.
26. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-94.
27. Sowinski KM, Lima JJ, Burlew BS, Massie JD, Johnson JA. Racial differences in propranolol enantiomer kinetics following simultaneous iv and oral administration. Br J Clin Pharmacol 1996;42:339-46.
28. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-42.
29. Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesylate with human P-glycoprotein. J Pharmacol Exp Ther 2003;307:824-8.
30. Judson I, Ma PM, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005;55:379-86.
31. Kretz O, Weiss HM, Schumacher MM, Gross G. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 2004;58:212-6.